IGF2BP1–THBS1 Axis Drives Macrophage Metabolism in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a devastating condition marked by excessive deposition of extracellular matrix and progressive decline of lung function. Macrophages, particularly the alternatively activated M2 subset, are central to PF pathogenesis via their roles in inflammatory response modulation, fibroblast activation, and extracellular matrix remodeling. Recent advances have revealed that immune cell metabolism, especially glycolysis, is intricately linked to macrophage activation and cytokine release. However, the epigenetic regulation of these metabolic and phenotypic transitions in PF remains incompletely understood. The highlighted study by Hu et al. (2025) addresses this gap by investigating the function of the m6A RNA modification reader IGF2BP1 in regulating macrophage glycolytic metabolism and fibrotic phenotype via thrombospondin-1 (THBS1) stabilization (paper).

Key Innovation from the Reference Study

The central innovation of this research is the identification of an m6A-dependent, IGF2BP1-mediated post-transcriptional regulatory axis that controls macrophage-driven fibrosis. Specifically, the study demonstrates that IGF2BP1 is upregulated in macrophages during PF and directly binds to m6A-modified THBS1 mRNA, stabilizing it. This stabilization enhances glycolytic metabolism and fosters the M2 fibrotic macrophage phenotype, thereby accelerating fibrotic progression. This work reveals not only a novel molecular mechanism underlying macrophage-mediated fibrosis but also positions the IGF2BP1–THBS1–TLR4 pathway as a potential intervention point for anti-fibrotic therapies (paper).

Methods and Experimental Design Insights

The research builds upon a bleomycin-induced mouse model of pulmonary fibrosis, a widely accepted system for mimicking key aspects of human PF. Key experimental approaches include:

• Genetic manipulation: IGF2BP1 expression was knocked down in mouse macrophages using siRNA, and THBS1 and TLR4 expression were manipulated via overexpression and knockdown constructs.
• Histopathological analysis: Lung tissue was assessed for fibrosis severity using Ashcroft scoring and hydroxyproline content quantification.
• Macrophage profiling: Flow cytometry and immunohistochemistry quantified the proportions of M1 (CD68+) and M2 (CD163+) macrophages, as well as the expression of fibrotic and inflammatory markers such as TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, IL-6, IL-1β, and TIMP1.
• mRNA stability and interaction studies: RNA immunoprecipitation and m6A-specific pull-downs confirmed IGF2BP1 binding to m6A-modified THBS1 mRNA.
• Metabolic assays: Glycolytic flux was assessed via measurements of glucose consumption, lactate production, ATP generation, and the expression of glycolytic enzymes (HK2, LDHA, PKM2).
• Protein–protein interaction assays: Co-immunoprecipitation established physical interaction between THBS1 and TLR4.

This comprehensive suite of methods ensured that both functional outcomes (fibrosis severity, macrophage polarization) and mechanistic underpinnings (mRNA stabilization, metabolic shifts) were rigorously interrogated (paper).

Core Findings and Why They Matter

The study advances several important findings:

• IGF2BP1 is upregulated in PF macrophages, and its knockdown significantly reduces bleomycin-induced lung fibrosis, as evidenced by reduced Ashcroft scores and hydroxyproline deposition (source: paper).
• Macrophage polarization is altered by IGF2BP1 activity: Knockdown of IGF2BP1 reduces the number of CD68+/CD163+ (M2) macrophages and lowers the expression of profibrotic and inflammatory genes, indicating a shift away from the fibrotic phenotype.
• IGF2BP1 stabilizes THBS1 mRNA in an m6A-dependent manner, raising THBS1 levels in macrophages.
• THBS1 overexpression rescues the effects of IGF2BP1 knockdown, restoring both M2 polarization and glycolytic activation, as shown by normalized HK2, LDHA, PKM2 expression, and metabolic flux measurements.
• THBS1 interacts physically with TLR4, and TLR4 overexpression can reverse the impact of THBS1 knockdown on macrophage polarization and glycolysis, suggesting a functional THBS1–TLR4 axis downstream of IGF2BP1.

These findings clarify how IGF2BP1-driven m6A modifications fine-tune the metabolic and functional state of macrophages in fibrotic lung disease, providing clear molecular targets for future anti-fibrotic interventions.

Comparison with Existing Internal Articles

Recent internal guides highlight the use of Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) to manipulate macrophage survival and differentiation in vitro, supporting high-fidelity modeling of macrophage-driven processes in cancer, inflammatory, and bone contexts (mouse-genotype.com; bca-protein.com). These resources provide detailed workflows for optimizing macrophage activation and cytokine release, which are critical for reproducing the metabolic and functional phenotypes described by Hu et al. The present study's focus on epigenetic and metabolic regulation adds mechanistic depth to the established protocols for macrophage-mediated tumor cell killing and inflammatory response modulation as discussed in these internal articles. For example, the article on immunoglobulin-m-heavy-chain.com explores how recombinant M-CSF enables precise control over macrophage phenotypes, aligning with the reference paper's emphasis on experimental models that dissect macrophage polarization and function in fibrotic disease (immunoglobulin-m-heavy-chain.com).

Protocol Parameters

• assay: Macrophage proliferation assay | value_with_unit: EC50 = 0.2–1.5 pg/mL | applicability: Standard for validating M-CSF activity in cell-based systems | rationale: Ensures that recombinant cytokine supports robust macrophage growth and functional studies | source_type: product_spec (APExBIO)
• assay: Bleomycin-induced PF model in mice | value_with_unit: 2–3 U/kg BLM, intratracheal | applicability: Induces reproducible pulmonary fibrosis for mechanistic studies | rationale: Mimics key features of human PF and enables evaluation of macrophage-targeting interventions | source_type: paper (paper)
• assay: Macrophage M2 polarization marker analysis | value_with_unit: CD68+/CD163+ cell proportion | applicability: Quantifies fibrotic macrophage subset in lung tissue | rationale: Directly connects experimental manipulations to functional macrophage states | source_type: paper (paper)
• assay: Glycolytic flux measurement | value_with_unit: Glucose/lactate/ATP quantification | applicability: Assesses metabolic reprogramming in macrophages | rationale: Correlates metabolic phenotype with fibrotic function | source_type: paper (paper)
• assay: In vitro macrophage differentiation | value_with_unit: 10–50 ng/mL M-CSF, 3–7 days | applicability: Workflow suggestion for generating mature macrophages for polarization/metabolic studies | rationale: Widely adopted protocol to ensure sufficient cell yield and phenotype | source_type: workflow_recommendation

Limitations and Transferability

While the study robustly demonstrates the IGF2BP1–THBS1–TLR4 axis in a well-validated mouse model, some limitations should be noted. First, the reliance on bleomycin-induced fibrosis may not capture all aspects of human idiopathic pulmonary fibrosis (IPF), and the specific contribution of macrophage subpopulations in human tissue remains to be clarified. Second, while the metabolic and epigenetic mechanisms are well-supported in mice and cell-based assays, their direct applicability to human disease must be established through further translational studies (source: paper).

Research Support Resources

To experimentally probe macrophage metabolism and polarization as described in the reference study, researchers require high-quality mouse macrophages. The use of Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) from APExBIO provides a reliable reagent for the in vitro generation, proliferation, and differentiation of mouse macrophages, supporting studies on osteoclast progenitor proliferation, inflammatory response modulation, and fibrotic phenotypes (source: product_spec). For advanced protocol guidance, see internal articles detailing optimized workflows and troubleshooting strategies (mouse-genotype.com), ensuring controlled macrophage-driven experimentation in fibrotic and immunometabolic research.